Time is running out to make your tax-deductible 2016 gift to OCRFA. We need your help. Over 22,000 women will be diagnosed with ovarian cancer in 2017. Over 200,000 women … Continued
Every year, 22,000 women are newly diagnosed with ovarian cancer. As OCRFA strives toward a cure and better treatments through research, we also provide patients and survivors with the care … Continued
(Dec. 21, 2016) Research published recently in Cancer Discovery suggests that cells in the fallopian tube previously thought to be precursors to high grade serous ovarian cancer may sometimes be … Continued
(Dec. 19, 2016) The U.S. Food and Drug Administration today granted accelerated approval to Rubraca (rucaparib) to treat women with a certain type of ovarian cancer. Rubraca is approved for … Continued
As the voice for women with ovarian cancer on Capitol Hill, OCRFA fights to secure funding for ovarian cancer research and education at the federal level. In 2016, with the … Continued
OCRFA-funded scientists are working hard to save women’s lives. In medical institutions across the country, they investigate the origins and biology of ovarian cancer, find new ways to identify and … Continued
Tickets are now available for the 2017 Turn Up the Heat! Gala in Washington DC. Turn Up the Heat features food from the top female chefs in DC and the … Continued
The Kolker Fellowship commemorates the legacy of pioneering health policy advocate Ann Kolker. At the time Ann was diagnosed with ovarian cancer in 1996, she was already a political powerhouse, having … Continued
(Dec. 9, 2016) This week Genentech announced that the US Food and Drug Administration has expanded approval for bevacizumab (Avastin) to include patients with platinum-sensitive, recurrent disease, either in combination … Continued
Recurrence is in the back of every ovarian cancer survivor’s mind. In this presentation, originally broadcast on November 28, 2016, Dr. Sarah Adams provided an overview of strategies for managing … Continued
OCRFA recently welcomed four new members to the Scientific Advisory Committee (SAC), our world-class group of leaders in the ovarian cancer field who review and approve all OCRFA research grants. … Continued
(Nov. 3, 2016) Senescence is the state when normal, healthy cells no longer have the ability to divide, which can occur during chemotherapy or when cancer genes within that cell … Continued
Get email updates about research news, action alerts, and ways to join the fight.
